Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 1

1(20.0%)

5Total

N/A(4)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04054453Not ApplicableUnknown

Prevention of Epilepsy by Reducing Neonatal Encephalopathy

Role: lead

NCT03409770Not ApplicableUnknown

Optimising the Duration of Cooling in Mild Encephalopathy

Role: lead

NCT02387385Not ApplicableCompleted

Hypothermia for Encephalopathy in Low and Middle-Income Countries Trial

Role: lead

NCT01760629Not ApplicableCompleted

Hypothermia for Encephalopathy in Low Income Countries-Feasibilty

Role: lead

NCT01120886Completed

Post-mortem Genetic Testing

Role: lead

NCT01417962Completed

Magnetic Resonance Imaging Autopsy Study

Role: lead

NCT01138176Phase 1Unknown

Whole Body Cooling Using Phase Changing Material

Role: collaborator

All 7 trials loaded